摘要
Prostate cancer (PCa) remains the most common malignancy and a leading cause of cancer-related 'deaths in men. Molecular discrimination at an early stage between indolent and aggressive primary tumors in pathologically confirmed PCa is required to develop personalized therapeutic interventions.
Prostate cancer (PCa) remains the most common malignancy and a leading cause of cancer-related 'deaths in men. Molecular discrimination at an early stage between indolent and aggressive primary tumors in pathologically confirmed PCa is required to develop personalized therapeutic interventions.